대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Long Term Outcome of Tamoxifen Therapy for Prevention and Management of Encapsulating Peritoneal Sclerosis in CAPD Patients: A Single-Center experience
저자	Hyejin Jung
출판정보	2026; 2026(1):
키워드	EPS, Tamoxifen, CAPD peritonitis
초록	Objectives: Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of CAPD. Tamoxifen has been used for the prevention and treatment of EPS; however, its long‑term outcomes have not been clearly evaluated in previous studies. Methods: We conducted a single‑center retrospective study of 30 adults with prior CAPD and at least one episode of CAPD peritonitis who subsequently received tamoxifen either prophylactically for EPS risk (n=10, 33.3%) or therapeutically for suspected or confirmed EPS or EPS‑related symptoms (n=20, 66.7%). Clinical records were reviewed for tamoxifen indication, dose, duration, symptom course, imaging findings, transition from CAPD to HD, kidney transplantation, and survival status at last follow‑up. Results: Tamoxifen was started at 10–20 mg/day in all 30 patients, and treatment duration exceeded 6 months in 22 (73.3%). Among 21 symptomatic patients, abdominal pain, distension, ileus, or refractory ascites improved in 13 (61.9%), usually within 1–3 months of tamoxifen initiation. Follow‑up imaging was available in 20 patients (66.7%), showing EPS progression in 6 (30.0%), stability in 9 (45.0%), and improvement in 5 (25.0%). In the prophylaxis group (n=10), definite EPS developed in 1 patient (10.0%) during long‑term follow‑up. After CAPD discontinuation, 11 patients (36.7%) remained on HD and 6 (20.0%) were alive with a functioning kidney transplant while 13 (43.3%) had died at last contact from various causes. Conclusion: In CAPD patients at risk of or affected by EPS, tamoxifen therapy was associated with symptom improvement in 13 of 21 symptomatic patients (61.9%) and radiologic stability or improvement in 14 of 20 (70.0%), whereas only 1 of 10 prophylactically treated patients (10.0%) developed definite EPS during follow‑up. These findings suggest that tamoxifen may offer meaningful clinical benefit in both the prevention and management of EPS. Larger controlled studies are needed to confirm its preventive and therapeutic value.
원문(PDF)	PDF 원문보기

목록

위로가기